Although it is unclear how modulators of cGMP levels regulate CTGF expression in the lung, riociguat has been shown to decrease CTGF expression in progressive cardiac remodeling and failure after myocardial infarction [52]. The gene discussed is CCN2; the disease is myocardial infarction.